Virological Response to Highly Active Antiretroviral Therapy in Patients Infected with Human Immunodeficiency Virus Type 2 (HIV-2) and in Patients Dually Infected with HIV-1 and HIV-2 in the Gambia and Emergence of Drug-resistant Variants

Overview

Journal J Clin Microbiol

Specialty Microbiology

Date 2009 May 8

PMID 19420165

Citations 30

Authors

Sabelle Jallow

Abraham Alabi

Ramu Sarge-Njie

Kevin Peterson

Hilton Whittle

Tumani Corrah

Assan Jaye

Matthew Cotten

Guido Vanham

Samuel J McConkey

Sarah Rowland-Jones

Wouter Janssens

Affiliations

Soon will be listed here.

Abstract

Drug design, antiretroviral therapy (ART), and drug resistance studies have focused almost exclusively on human immunodeficiency virus type 1 (HIV-1), resulting in limited information for patients infected with HIV-2 and for those dually infected with HIV-1 and HIV-2. In this study, 20 patients, 12 infected with HIV-2 and 8 dually infected with HIV-1 and HIV-2, all treated with zidovudine (ZDV), lamivudine (3TC), and lopinavir-ritonavir (LPV/r), were followed up longitudinally for about 3 years. For 19/20 patients, viral loads were reduced to undetectable levels; the patient whose viral load remained detectable reported adverse effects associated with LPV/r that had caused him to stop taking all the drugs. HIV-2 strains containing mutations in both the protease and the reverse transcriptase gene that may confer drug resistance were observed in two patients with viral rebound, as early as 130 days (4.3 months) after the initiation of therapy. We conclude that the combination of ZDV, 3TC, and LPV/r is able to provide efficient and durable suppression of HIV-1 and HIV-2 for as long as 3 years in HIV-2-infected and dually infected patients. However, the emergence of HIV-1 and HIV-2 strains containing drug-resistant mutations can compromise the efficacy of this highly active ART.

Citing Articles

Evaluation of HIV infection in febrile patients visiting health centers in Lagos, Nigeria.

Akinnusi O, Bello A, Adeleye I, Nutor J BMC Res Notes. 2022; 15(1):71.

PMID: 35183247 PMC: 8858461. DOI: 10.1186/s13104-022-05961-0.

Long-term Experience and Outcomes of Programmatic Antiretroviral Therapy for Human Immunodeficiency Virus Type 2 Infection in Senegal, West Africa.

Raugi D, Ba S, Cisse O, Diallo K, Tamba I, Ndour C Clin Infect Dis. 2021; 72(3):369-378.

PMID: 33527119 PMC: 7850514. DOI: 10.1093/cid/ciaa277.

Structural Impacts of Drug-Resistance Mutations Appearing in HIV-2 Protease.

Laville P, Petitjean M, Regad L Molecules. 2021; 26(3).

PMID: 33503916 PMC: 7865771. DOI: 10.3390/molecules26030611.

Survival among antiretroviral-experienced HIV-2 patients experiencing virologic failure with drug resistance mutations in Cote d'Ivoire West Africa.

Tchounga B, Charpentier C, Coffie P, Dabis F, Descamps D, Eholie S PLoS One. 2020; 15(8):e0236642.

PMID: 32756581 PMC: 7406077. DOI: 10.1371/journal.pone.0236642.

Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease.

Laville P, Fartek S, Cerisier N, Flatters D, Petitjean M, Regad L BMC Mol Cell Biol. 2020; 21(1):46.

PMID: 32576133 PMC: 7310402. DOI: 10.1186/s12860-020-00290-1.

References

Gulick R, Mellors J, Havlir D, Eron J, Gonzalez C, McMahon D . Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997; 337(11):734-9. DOI: 10.1056/NEJM199709113371102. View

Descamps D, Collin G, Letourneur F, Apetrei C, Damond F, Simon F . Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 1997; 71(11):8893-8. PMC: 192360. DOI: 10.1128/JVI.71.11.8893-8898.1997. View

Rodes B, Sheldon J, Toro C, Jimenez V, Angel Alvarez M, Soriano V . Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J Antimicrob Chemother. 2006; 57(4):709-13. DOI: 10.1093/jac/dkl034. View

Hansmann A, Schim van der Loeff M, Kaye S, Awasana A, Sarge-Njie R, ODonovan D . Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia. J Acquir Immune Defic Syndr. 2005; 38(3):335-41. View

Kuritzkes D, Bassett R, Hazelwood J, Barrett H, Rhodes R, Young R . Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J Acquir Immune Defic Syndr. 2004; 36(1):600-3. DOI: 10.1097/00126334-200405010-00008. View

Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R . Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J Hum Virol. 1999; 1(7):457-68. View

Damond F, Brun-Vezinet F, Matheron S, Peytavin G, Campa P, Pueyo S . Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J Clin Microbiol. 2005; 43(1):484-7. PMC: 540186. DOI: 10.1128/JCM.43.1.484-487.2005. View

Hammer S, Squires K, Hughes M, Grimes J, Demeter L, Currier J . A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997; 337(11):725-33. DOI: 10.1056/NEJM199709113371101. View

Isaka Y, Miki S, Kawauchi S, Suyama A, Sugimoto H, Adachi A . A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch Virol. 2001; 146(4):743-55. DOI: 10.1007/s007050170143. View

10.

Colson P, Henry M, Tivoli N, Gallais H, Gastaut J, Moreau J . Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J Med Virol. 2005; 75(3):381-90. DOI: 10.1002/jmv.20296. View

11.

Holmgren B, Da Silva Z, Vastrup P, Larsen O, Andersson S, Ravn H . Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau. Retrovirology. 2007; 4:85. PMC: 2222662. DOI: 10.1186/1742-4690-4-85. View

12.

MacNeil A, Sarr A, Sankale J, Meloni S, Mboup S, Kanki P . Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol. 2007; 81(10):5325-30. PMC: 1900238. DOI: 10.1128/JVI.02625-06. View

13.

Poveda E, Rodes B, Toro C, Soriano V . Are fusion inhibitors active against all HIV variants?. AIDS Res Hum Retroviruses. 2004; 20(3):347-8. DOI: 10.1089/088922204322996590. View

14.

Kaye S . Simple PCR-based method for synthesis of molecular calibrators and controls. Clin Chem. 2003; 49(2):325-7. DOI: 10.1373/49.2.325. View

15.

Jaye A, Sarge-Njie R, Schim van der Loeff M, Todd J, Alabi A, Sabally S . No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients. J Infect Dis. 2004; 189(3):498-505. DOI: 10.1086/381185. View

16.

Brandin E, Lindborg L, Gyllensten K, Brostrom C, Hagberg L, Gisslen M . pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res Hum Retroviruses. 2003; 19(7):543-50. DOI: 10.1089/088922203322230905. View

17.

Palella Jr F, Delaney K, Moorman A, Loveless M, Fuhrer J, Satten G . Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998; 338(13):853-60. DOI: 10.1056/NEJM199803263381301. View

18.

Adje-Toure C, Cheingsong R, Garcia-Lerma J, Eholie S, Borget M, Bouchez J . Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance profiles of patients treated in Abidjan, Côte d'Ivoire. AIDS. 2003; 17 Suppl 3:S49-54. View

19.

Johnson V, Brun-Vezinet F, Clotet B, Kuritzkes D, Pillay D, Schapiro J . Update of the drug resistance mutations in HIV-1: Fall 2006. Top HIV Med. 2006; 14(3):125-30. View

20.

Kanki P, Travers K, Mboup S, Hsieh C, Marlink R, Gueye-Ndiaye A . Slower heterosexual spread of HIV-2 than HIV-1. Lancet. 1994; 343(8903):943-6. DOI: 10.1016/s0140-6736(94)90065-5. View